Keith Williams retires as Proteome director, remains as consultant
11 November, 2005 by Ruth BeranProteome Systems (ASX:PXL) founder Dr Keith Williams is no longer a director of the company he established in 1999, following his decision to withdraw his nomination for re-election at yesterday's AGM.
Mimotopes to team with Genzyme in peptide supply deal
10 November, 2005 by Helen SchullerPharmAust (ASX:PAA) subsidiary Mimotopes will team up with US-based Genzyme Pharmaceuticals in a strategic alliance to provide peptide products and services to both companies' customers globally.
How a code of practice can help manage biotech's conundrum
10 November, 2005 by Michael AldridgeThe new AusBiotech/ASX code of practice for reporting by life science companies, launched last week, is being hailed as an important milestone in the development of the Australian biotech sector. Here, Michael Aldridge, who was on the committee to review the code's first draft, explains why he believes the code is so important to the industry.
Avexa and CSIRO to collaborate
09 November, 2005 by Ruth BeranMelbourne-based Avexa (ASX:AVX) and the CSIRO have entered into a collaboration deal to discover new drugs for the treatment of human viral diseases.
AtCor lists on ASX ahead of schedule
09 November, 2005 by Helen SchullerShares in AtCor Medical (ASX:ACG), the developer and marketer of a device to measure cardiovascular function, began trading on the Australian Stock Exchange today at $0.65, 7.5 per cent above its issue price of $0.50.
Pharmaxis sets US share price at $33
09 November, 2005 by Helen SchullerDrug developer Pharmaxis (ASX:PXS) has set the pricing of an underwritten public offering of 1,300,000 American Depositary Shares at a price of US$24.16 (AUD$33) per ADS.
Vale Jamie Callachor
08 November, 2005 by Staff WritersThe NSW biotech community has been saddened by the loss of Jamie Callachor, who passed away on November 2.
Qld to join synchrotron
08 November, 2005 by Ruth BeranThe Queensland government and a consortium of Queensland universities will together invest AUD$5 million in the Melbourne-based Australian Synchrotron.
CRO Datapharm to team with e-diary firm
07 November, 2005 by Ruth BeranAustralian contract research organisation Datapharm has entered into a strategic alliance with Brussels and Cambridge based Symfo, a specialist in electronic diary solutions for patients.
Phosphagenics signs development agreement with US firm ALZA
07 November, 2005 by Helen SchullerMelbourne's Phosphagenics (ASX:POH) has entered into an agreement with US-based ALZA Corp to determine the feasibility of delivering a number of compounds nominated by ALZA using Phosphagenics' patented transdermal delivery system, TPM-01.
Peptech to step up R&D after profit boost
07 November, 2005 by Ruth BeranSydney-based Peptech (ASX:PTD) expects to boost its R&D spend in the next year, in the wake of a net profit of AUD$25.7 million for the year ended September 30.
Novogen says remuneration vote subject to proxy error
07 November, 2005 by Ruth BeranNovogen (ASX:NRT) has cited a "voting systems error" as the reason why a significant number of proxy votes were cast against the resolution to adopt the company's remuneration report for the year ended June 30 at its AGM in late October.
LabTech to raise $5.5 million, list on ASX
07 November, 2005 by Helen SchullerSouth Australia's LabTech Systems (NSX:LTS) has lodged a prospectus for an IPO to raise up to AUD$5.5 million to progress the development of its MicroStreak technology and assist in moving the company's shares and options from the Newcastle Stock Exchange to the Australian Stock Exchange.
SSH Medical re-lists with Bio-Layer
07 November, 2005 by Ruth BeranSSH Medical (ASX:SSH) re-listed today on the ASX following a capital raising of AUD$4.26 million and the acquisition of unlisted Brisbane-based materials sciences specialist Bio-Layer.
SciGen partner increases investment
04 November, 2005 by Helen SchullerThe two largest shareholders in Singapore-based, ASX-listed biopharmaceutical company SciGen (ASX:SIE), SciTech Medical and Bioton, have entered into a share exchange agreement which may result in Bioton gaining a 44.7 per cent equity share in SciGen.
